Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one ...

Modulating the neuroinflammatory response using the nasal spray, Izzy said ... The study examines the monoclonal antibody Foralumab, made by Tiziana, which has been tested in clinical trials ...

When delivered intravenously, foralumab kills T cells, but when introduced into the mucosa, either orally or intranasally, it stimulates T-regs instead. For trials of AD and other disorders, the ...

In parallel with these encouraging results, Tiziana Life Sciences has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial to further assess the efficacy and safety of nasal ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...